WO2011126842A3 - Targeting micrornas for the treatment of cardiac disorders - Google Patents
Targeting micrornas for the treatment of cardiac disorders Download PDFInfo
- Publication number
- WO2011126842A3 WO2011126842A3 PCT/US2011/030341 US2011030341W WO2011126842A3 WO 2011126842 A3 WO2011126842 A3 WO 2011126842A3 US 2011030341 W US2011030341 W US 2011030341W WO 2011126842 A3 WO2011126842 A3 WO 2011126842A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- cardiac disorders
- targeting micrornas
- micrornas
- targeting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Provided herein are methods and compositions for the treatment of cardiac disease using an inhibitor of miR-21.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31920010P | 2010-03-30 | 2010-03-30 | |
| US61/319,200 | 2010-03-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2011126842A2 WO2011126842A2 (en) | 2011-10-13 |
| WO2011126842A3 true WO2011126842A3 (en) | 2011-12-01 |
Family
ID=44763489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2011/030341 Ceased WO2011126842A2 (en) | 2010-03-30 | 2011-03-29 | Targeting micrornas for the treatment of cardiac disorders |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2011126842A2 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8815826B2 (en) | 2010-07-23 | 2014-08-26 | Regulus Therapeutics, Inc. | Targeting microRNAs for the treatment of fibrosis |
| NZ717921A (en) | 2011-04-25 | 2017-09-29 | Regulus Therapeutics Inc | Microrna compounds and methods for modulating mir-21 activity |
| EP2592145A1 (en) * | 2011-11-11 | 2013-05-15 | Medizinische Hochschule Hannover | Medicament for the treatment of cardiac disease |
| PH12023550488A1 (en) | 2012-04-25 | 2024-06-24 | Sanofi Sa | Microrna compounds and methods for modulating mir-21 activity |
| UA116639C2 (en) | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Methods for treatment of alport syndrome |
| EP3548005A4 (en) | 2016-11-29 | 2020-06-17 | Puretech Health LLC | EXOSOME FOR THE OUTPUT OF THERAPEUTIC ACTIVE SUBSTANCES |
| CN110650742A (en) * | 2017-03-17 | 2020-01-03 | 国立大学法人千叶大学 | Novel cancer treatment using structurally enhanced S-TuD |
| EP3813941A1 (en) * | 2018-06-28 | 2021-05-05 | United Kingdom Research and Innovation | Microrna targeting agent for treatment of heart disease |
| CN109498642A (en) * | 2018-12-21 | 2019-03-22 | 复旦大学附属中山医院 | A kind of target therapeutic agent of microvascular lesion caused by Infected with Coxsackievirus B 3 |
| CN115961025B (en) * | 2020-06-30 | 2023-07-18 | 苏州大学附属第二医院 | Application of circular RNA in preparation of products related to myocardial hypertrophy |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009058818A2 (en) * | 2007-10-29 | 2009-05-07 | The Board Of Regents Of The University Of Texas System | Compositions comprising a micro-rna and methods of their use in regulating cardiac remodeling |
| WO2009106367A1 (en) * | 2008-02-27 | 2009-09-03 | Julius Maximilians-Universität Würzburg | Microrna (mirna) and downstream targets for diagnostic and therapeutic purposes |
-
2011
- 2011-03-29 WO PCT/US2011/030341 patent/WO2011126842A2/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009058818A2 (en) * | 2007-10-29 | 2009-05-07 | The Board Of Regents Of The University Of Texas System | Compositions comprising a micro-rna and methods of their use in regulating cardiac remodeling |
| WO2009106367A1 (en) * | 2008-02-27 | 2009-09-03 | Julius Maximilians-Universität Würzburg | Microrna (mirna) and downstream targets for diagnostic and therapeutic purposes |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011126842A2 (en) | 2011-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2011126842A3 (en) | Targeting micrornas for the treatment of cardiac disorders | |
| WO2014036219A3 (en) | Methods and compositions for treatment of a genetic condition | |
| WO2011083150A3 (en) | Obesity small molecules | |
| WO2012058693A3 (en) | Compositions and methods for inhibition of pcsk9 genes | |
| WO2010102112A9 (en) | Treatment of drug-related side effect and tissue damage by targeting the cd24-hmgb1-siglec10 axis | |
| WO2012125544A3 (en) | Necroptosis inhibitors and methods of use therefor | |
| EP2435825B8 (en) | Methods of treating diseases | |
| WO2013018060A3 (en) | Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions | |
| WO2013023084A3 (en) | Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells | |
| AP2014007804A0 (en) | Compositions and methods for the treatment of hepatic diseases and disorders. | |
| WO2011150201A3 (en) | Azolyl amide compounds and methods of use thereof | |
| WO2013023059A3 (en) | Methods and compositions for the treatment of autoimmune and inflammatory diseases | |
| WO2012012716A3 (en) | Targeting micrornas for the treatment of fibrosis | |
| WO2013059233A3 (en) | Thermoresponsive compositions for dermatological use and methods thereof | |
| WO2012064743A3 (en) | Methods for improving heart function | |
| WO2011130697A3 (en) | Tissue targeting | |
| WO2011153429A9 (en) | Methods of treatment | |
| WO2012078519A3 (en) | 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2 | |
| EP2590651B8 (en) | New drug combinations for the treatment of malaria | |
| WO2012082942A3 (en) | Neuropeptide analogs, compositions, and methods for treating pain | |
| WO2011116351A3 (en) | Methods and compositions for the treatment of cancer | |
| WO2013009979A3 (en) | Compositions and methods for suppressing gene expression of p53 and clusterin | |
| WO2012051165A3 (en) | Mir-211 expression and related pathways in human melanoma | |
| WO2013009678A3 (en) | Compositions and methods for the treatment of norovirus infection | |
| HK40114855A (en) | Rna modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11766462 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 11766462 Country of ref document: EP Kind code of ref document: A2 |